Page Title
Clinical Trial Finder
Observational Closed to Enrollment
Exploring Attitudes Toward Nutrition (EATN) (EATN22PE0)
This qualitative multi-site longitudinal study is designed to analyze the perspectives about what nutrition means to people with CF, behavioral and psychosocial factors that support or hinder optimal nutrition, and strategies/interventions to improve nutritional status. Participants will be asked to participate in up to two interviews. Trained research staff will conduct semi-structured interviews using descriptive phenomenological research methods that will be audio-recorded and transcribed for thematic analysis. Each interview will last between 30-60 minutes.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants in this study may also be enrolled in the STRONG-CF study.
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
6 weeks -
Number of Study Visits:
2
Additional Information
-
Phase: ?more info
Not Applicable -
Study Sponsor: ?more info
Bruce, Amanda -
Study Drugs:
N/A
Study Sites
-
Closed to Enrollment
California
Stanford University Medical Center, Palo Alto, CA 94304
-
Closed to Enrollment
Kansas
University of Kansas Medical Center, Kansas City, KS 66160
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Boston, MA 02115
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
No FEV1 Limit
Other Primary Eligibility Criteria
Participants in this study may also be enrolled in the STRONG-CF study.
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More